Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sinopharm Group Co ( (HK:1099) ) just unveiled an update.
Sinopharm Group Co. Ltd. announced the unaudited financial results for its subsidiary, Sinopharm Accord, for the first half of 2025. The company reported a slight decrease in revenue by 2.62% to RMB 36.8 billion and a 10.43% drop in net profit attributable to shareholders. The net cash flow from operating activities significantly declined by 98.38%, indicating potential operational challenges. Despite these declines, total assets increased by 6.04%, reflecting some growth in asset base. The announcement may impact stakeholders’ perception of the company’s financial health and operational efficiency.
The most recent analyst rating on (HK:1099) stock is a Buy with a HK$20.50 price target. To see the full list of analyst forecasts on Sinopharm Group Co stock, see the HK:1099 Stock Forecast page.
More about Sinopharm Group Co
Sinopharm Group Co. Ltd. operates in the pharmaceutical industry, focusing on the distribution of medicines and healthcare products. It is a major player in the Chinese market, with its subsidiary Sinopharm Accord listed on the Shenzhen Stock Exchange.
Average Trading Volume: 6,135,372
Technical Sentiment Signal: Buy
Current Market Cap: HK$58.01B
Learn more about 1099 stock on TipRanks’ Stock Analysis page.